In bladder cancer (BLCA) cells, the downregulation of NAT10 expression reduces the ac4C modification of mRNA in specific regions, which in turn impairs the translation stability and efficiency of target genes such as BCL9-like gene (BCL9L), SRY-box transcription factor 4 gene (SOX4), and AKT serine/threonine kinase 1 (AKT1) [35]. The gene discussed is AKT1; the disease is urinary bladder carcinoma.